Breaking research could help to advance care for overdose patients who've taken xylazine

New findings published in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's) journal, Clinical Chemistry

WASHINGTON, Nov. 20, 2024 /PRNewswire/ -- A novel study published today in ADLM's journal, Clinical Chemistry, has found that it takes the human body much longer than previously thought to clear xylazine — one of the most popular emerging drugs of abuse in the U.S. This much-needed insight into how the body processes xylazine could improve treatment of overdose patients who've taken it.

View the full study here: https://doi.org/10.1093/clinchem/hvae163

Xylazine has traditionally been used in veterinary practice as a tranquilizer, but between 2019 and 2022, detection of xylazine in fentanyl-associated overdose deaths soared by 276%, according to a report from the Centers for Disease Control and Prevention. This is particularly concerning because, since xylazine's not an opioid, Narcan doesn't work in reviving people who've taken it. Complicating matters further is the fact that xylazine has been studied very little in humans, which means that healthcare providers don't have all the information they need to treat patients who've used it.

In an effort to help close this gap in knowledge about the drug, a team of researchers led by Bridgit Crews, PhD, associate professor of pathology and immunology at the Washington University School of Medicine in St. Louis, set out to determine how long xylazine remains in the body. The team initially identified 493 patients who'd used xylazine, nearly all of whom also tested positive for fentanyl. Of these, 28 met the study criteria and had blood samples available that could be used to assess xylazine's half-life, which is the amount of time it takes for the blood concentration of a drug to drop to half of its initial amount. To estimate xylazine's half-life, the researchers analyzed the blood samples and plotted the concentration of xylazine in the blood over time.

The results showed that the average half-life of xylazine in the blood is 12 hours, which is longer than that found in several animal species and in a single human case study that showed a half-life of nearly 5 hours in the blood. This suggests that xylazine stays in the human body for up to 2 days after an individual's last exposure, depending on the amount ingested.

Additionally, the team identified metabolites — substances produced during the body's breakdown of a drug — that could help improve identification of xylazine in future studies, as well as clinical testing for the drug.

"There is scarce information on the pharmacokinetics of xylazine in humans, particularly in those who may chronically use fentanyl mixed with xylazine," Crews said. "A better understanding of typical xylazine concentrations encountered in individuals who use fentanyl mixed with xylazine, as well as the duration that xylazine remains detectable in blood, may help to improve the interpretation of clinical studies, provide evidence to support appropriate cutoffs for xylazine surveillance, and potentially inform treatment and/or patient monitoring or risk mitigation strategies."

About the Association for Diagnostics & Laboratory Medicine (ADLM)

Dedicated to achieving better health through laboratory medicine, ADLM (formerly AACC) brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, ADLM has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.myadlm.org.

Clinical Chemistry (clinchem.org) is the leading international journal of laboratory medicine, featuring nearly 400 peer-reviewed studies every year that help patients get accurate diagnoses and essential care. This vital research is advancing areas of healthcare ranging from genetic testing and drug monitoring to pediatrics and appropriate test utilization.

Christine DeLong
ADLM
Associate Director, Communications & PR
(p) 202.835.8722
[email protected]

Molly Polen
ADLM
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
[email protected]

SOURCE Association for Diagnostics & Laboratory Medicine (ADLM)